Combinations of dendritic cell-based vaccines and checkpoint inhibitors
Patent Information
- Application Number
- HK62026124722
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-07
- Filing Date
- 2026-06-12
- Publication Date
- 2026-07-31
Smart Images
Figure 00000043_0000 
Figure 00000043_0001 
Figure 00000044_0000
Abstract
Description
This article provides methods and materials for using a combination of Th17 DC vaccines and immune checkpoint inhibitors to treat cancers (e.g., ovarian cancer). Abstract
Claims
WHAT IS CLAIMED IS:
1. A method for treating a mammal having cancer, wherein said method comprises:(a) administering, to said mammal, an effective amount of a vaccine composition capable of activating T cells within said mammal to form activated IL-17-secreting T cells that can recognize one or more antigens expressed by said cancer, and(b) administering, to said mammal, an effective amount of an immune checkpoint inhibitor (ICI).
2. The method of claim 1, wherein said mammal is a human.
3. The method of claim 1, wherein said cancer is ovarian cancer, melanoma, chronic lymphocytic leukemia, gastric cancer, cervical cancer, colorectal cancer, breast cancer, or lung cancer.
4. The method of claim 1, wherein said vaccine composition comprises dendritic cells (DCs) presenting one or more folate receptor alpha (FRa) antigens.
5. The method of claim 4, wherein said one or more FRa antigens comprise one or more peptides having the amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO: 14.
6. The method of claim 1, wherein said method comprises administering a dose of about 5 x 106to about 50 x 106of said DCs composition to said mammal.
7. The method of claim 1, wherein said method comprises administering said vaccine composition to said mammal two or more times over a time period of about 2 weeks to about 16 weeks.
8. The method of claim 1, wherein said ICI is selected from the group consisting of pembrolizumab, atezolizumab, nivolumab, durvalumab, avelumab, tremelimumab, ipilimumab, and cemiplimab.
9. The method of claim 1, wherein said method comprises administering a dose of about 50 mg to about 1500 mg of said ICI to said mammal.
10. The method of claim 1, wherein said method comprises administering said ICI to said mammal two or more times over a time period of about 2 weeks to about 16 weeks.
11. The method of claim 1, wherein said method further comprises monitoring said mammal after said administering steps (a) and (b) to determine an effect of said vaccine composition and said ICI on said mammal.
12. The method of claim 11, wherein said monitoring comprises using computed tomography, positron emission tomography / computed tomography, bone scan, or magnetic resonance imaging.
13. The method of claim 12, wherein said monitoring comprises measuring the level of one or more biomarkers in a tumor biopsy obtained from said mammal after said administering steps (a) and (b), wherein said one or more biomarkers are selected from the group consisting of CCL6, CX3CL1, CXCL16, GM-CSF, ICAM-1, IL-la, LIX, osteoprotegerin, and RBP-4.